松龄血脉康胶囊联合苯磺酸氨氯地平对肝阳上亢型高血压病人血浆MDA、NOS、SOD活性及血压变异性的影响
|
摘要
目的观察松龄血脉康胶囊联合苯磺酸氨氯地平对肝阳上亢型高血压病人血浆丙二醛(MDA)、一氧化氮合酶(NOS)、超氧化物歧化酶(SOD)活性及血压变异性(BPV)的影响。方法将94例肝阳上亢型高血压病人按照随机数字表法分为观察组与对照组,各47例。对照组给予苯磺酸氨氯地平治疗,观察组在对照组基础上加用松龄血脉康胶囊治疗,两组均持续治疗4周。观察两组临床疗效、中医证候积分、血浆MDA、NOS、SOD活性、血压及血压变异性,比较两组不良反应。结果观察组总有效率为97.87%,显著高于对照组的82.98%(P<0.05);治疗后,两组中医证候积分均显著降低(P<0.05),且观察组显著低于对照组(P<0.05);治疗后,两组血浆MDA水平显著降低(P<0.05),血浆NOS、SOD活性显著升高(P<0.05),且观察组显著优于对照组(P<0.05);治疗后,两组24 h平均收缩压(24 h SBP)、24 h平均舒张压(24 h DBP)、24 h平均收缩压变异性(24 h SBPV)、24 h平均舒张压变异性(24 h DBPV)均显著降低(P<0.05),且观察组显著低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论松龄血脉康胶囊联合苯磺酸氨氯地平治疗肝阳上亢型高血压,可改善血浆MDA、NOS、SOD活性,降低BPV。
Objective To investigate the effects of Songling Xuemaikang capsule(SXC) and amlodipine besylate on plasma malondialdehyde(MDA),nitric oxide synthase(NOS),superoxide dismutase(SOD) activities and blood pressure variability(BPV) in hypertensive patients with liver-yang hyperactivity syndrome.Methods Ninety-four hypertensive patients with liver-yang hyperactivity syndrome were randomly divided into two groups:control group(n=47) treated with amlodipine besylate,and observation group(n=47) treated with SXC and amlodipine besylate for 4 weeks.The clinical efficacy,traditional Chinese medicine(TCM) syndrome score,plasma MDA,NOS,SOD activities,blood pressure, and BPV were observed.The adverse reactions were compared between the two groups.Results The total effective rate was significantly higher in observation group than that in control group(97.87% vs.82.98%,P<0.05).After treatment,TCM syndromes scores and plasma MDA levels were significantly lower in two groups(P<0.05),which was significantly lower in the observation group than that in the control group(P<0.05).After treatment,plasma NOS,SOD activities levels in two groups were significantly higher(P<0.05),which was significantly higher in the observation group than that in the control group(P<0.05).After treatment,24 h average systolic blood pressure(24 h SBP),24 h average diastolic blood pressure(24 h DBP),24 h average systolic BPV(24 h SBPV),24 h average diastolic BPV(24 h DBPV) were significantly lower in two groups(P<0.05),which was significantly lower in the observation group than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion SXC and amlodipine besylate can improve the activity of MDA,NOS,SOD,and decrease BPV in patients hypertensive patients with liver-yang hyperactivity syndrome.
Objective To investigate the effects of Songling Xuemaikang capsule(SXC) and amlodipine besylate on plasma malondialdehyde(MDA),nitric oxide synthase(NOS),superoxide dismutase(SOD) activities and blood pressure variability(BPV) in hypertensive patients with liver-yang hyperactivity syndrome.Methods Ninety-four hypertensive patients with liver-yang hyperactivity syndrome were randomly divided into two groups:control group(n=47) treated with amlodipine besylate,and observation group(n=47) treated with SXC and amlodipine besylate for 4 weeks.The clinical efficacy,traditional Chinese medicine(TCM) syndrome score,plasma MDA,NOS,SOD activities,blood pressure, and BPV were observed.The adverse reactions were compared between the two groups.Results The total effective rate was significantly higher in observation group than that in control group(97.87% vs.82.98%,P<0.05).After treatment,TCM syndromes scores and plasma MDA levels were significantly lower in two groups(P<0.05),which was significantly lower in the observation group than that in the control group(P<0.05).After treatment,plasma NOS,SOD activities levels in two groups were significantly higher(P<0.05),which was significantly higher in the observation group than that in the control group(P<0.05).After treatment,24 h average systolic blood pressure(24 h SBP),24 h average diastolic blood pressure(24 h DBP),24 h average systolic BPV(24 h SBPV),24 h average diastolic BPV(24 h DBPV) were significantly lower in two groups(P<0.05),which was significantly lower in the observation group than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion SXC and amlodipine besylate can improve the activity of MDA,NOS,SOD,and decrease BPV in patients hypertensive patients with liver-yang hyperactivity syndrome.
引文
[1] 庞科,邹凡文.重庆市永川区高血压前期流行病学特点及影响因素分析[J].重庆医学,2014,43(35):4781-4783.
[2] 史振仙,李龙,胡敏,等.叶酸联合钙离子拮抗剂治疗老年高血压患者对血压、同型半胱氨酸等水平的影响[J].疑难病杂志,2016,15(10):1006-1009.
[3] 陈慧敏,许逸飞.苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床研究[J].中国临床药理学杂志,2016,32(12):1072-1074.
[4] 潘敬顺.中医药治疗高血压病研究进展[J].解放军医药杂志,2016,28(3):101-103.
[5] 中国高血压防治指南修订委员会.中国高血压防治指南(2010年修订版)[J].中国实用乡村医生杂志,2012,19(12):1-15.
[6] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:73-76.
[7] 金楠,李革,李会,等.中国大陆地区成年人高血压前期发生率及危险因素的meta分析[J].南方医科大学学报,2013,33(12):1738-1743.
[8] 邢占良,舒宝瑞,刘春玲,等.葛根素联合替米沙坦对肥胖性高血压患者氧化应激和血管内皮功能的影响[J].河北医药,2016,38(15):2299-2301.
[9] RUBATTU S,PAGLIARO B,PIERELLI G,et al.Pathogenesis of target organ damage in hypertension:role of mitochondrial oxidative stress[J].Int J Mol Sci,2015,16(1):823-839.
[10] 王伟,韩卫星,胡华青,等.维生素D不足或缺乏的高血压患者血清SOD活性、MDA含量变化及其意义[J].山东医药,2016,56(31):61-63.
[11] 兰行远,徐尚华.替米沙坦对冠心病合并高血压患者血管内皮功能及炎症因子的影响[J].中国医药导报,2015,12(33):142-145.
[12] KRUZLIAK P,KOVACOVA G,PECHANOVA O.Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension[J].Angiogenesis,2013,16(2):289-295.
[13] NWOKOCHA C R,BAKER A,DOUGLAS D,et al.Apocynin ameliorates cadmium-induced hypertension through elevation of endothelium nitric oxide synthase[J].Cardiovascular Toxicology,2013,13(4):357-363.
[14] 康健,赵兴山,丁幼楠.血压变异性对老年女性高血压患者颈动脉硬化的影响[J].中华老年心脑血管病杂志,2015,17(2):200-202.
[15] 彭朝明,黄吟雪,田鹏,等.苯磺酸氨氯地平和莫索尼定对老年高血压患者血压变异性和血清脂联素水平的影响[J].成都医学院学报,2016,11(3):300-302.
[16] 王艳霞,张艳,柳士博,等.高血压病眩晕的中医病机及治法[J].长春中医药大学学报,2014,30(5):847-849.
[17] 郑丽维,俞晓莲,陈丰,等.按摩四关穴对肝阳上亢证高血压患者的效果观察[J].中华护理杂志,2015,50(11):1322-1326.
[18] 李聪,李鹏,李志浩,等.马尾松松针的研究概况[J].国际中医中药杂志,2013,35(8):748-750.
[19] 程博琳,苗明三.葛根现代研究及应用特点分析[J].中医学报,2014,29(7):1014-1016.
[20] 韩珮,张春椿,熊耀康.珍珠粉临床应用的最新研究进展[J].中医学报,2011,26(7):835-837.
[2] 史振仙,李龙,胡敏,等.叶酸联合钙离子拮抗剂治疗老年高血压患者对血压、同型半胱氨酸等水平的影响[J].疑难病杂志,2016,15(10):1006-1009.
[3] 陈慧敏,许逸飞.苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床研究[J].中国临床药理学杂志,2016,32(12):1072-1074.
[4] 潘敬顺.中医药治疗高血压病研究进展[J].解放军医药杂志,2016,28(3):101-103.
[5] 中国高血压防治指南修订委员会.中国高血压防治指南(2010年修订版)[J].中国实用乡村医生杂志,2012,19(12):1-15.
[6] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:73-76.
[7] 金楠,李革,李会,等.中国大陆地区成年人高血压前期发生率及危险因素的meta分析[J].南方医科大学学报,2013,33(12):1738-1743.
[8] 邢占良,舒宝瑞,刘春玲,等.葛根素联合替米沙坦对肥胖性高血压患者氧化应激和血管内皮功能的影响[J].河北医药,2016,38(15):2299-2301.
[9] RUBATTU S,PAGLIARO B,PIERELLI G,et al.Pathogenesis of target organ damage in hypertension:role of mitochondrial oxidative stress[J].Int J Mol Sci,2015,16(1):823-839.
[10] 王伟,韩卫星,胡华青,等.维生素D不足或缺乏的高血压患者血清SOD活性、MDA含量变化及其意义[J].山东医药,2016,56(31):61-63.
[11] 兰行远,徐尚华.替米沙坦对冠心病合并高血压患者血管内皮功能及炎症因子的影响[J].中国医药导报,2015,12(33):142-145.
[12] KRUZLIAK P,KOVACOVA G,PECHANOVA O.Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension[J].Angiogenesis,2013,16(2):289-295.
[13] NWOKOCHA C R,BAKER A,DOUGLAS D,et al.Apocynin ameliorates cadmium-induced hypertension through elevation of endothelium nitric oxide synthase[J].Cardiovascular Toxicology,2013,13(4):357-363.
[14] 康健,赵兴山,丁幼楠.血压变异性对老年女性高血压患者颈动脉硬化的影响[J].中华老年心脑血管病杂志,2015,17(2):200-202.
[15] 彭朝明,黄吟雪,田鹏,等.苯磺酸氨氯地平和莫索尼定对老年高血压患者血压变异性和血清脂联素水平的影响[J].成都医学院学报,2016,11(3):300-302.
[16] 王艳霞,张艳,柳士博,等.高血压病眩晕的中医病机及治法[J].长春中医药大学学报,2014,30(5):847-849.
[17] 郑丽维,俞晓莲,陈丰,等.按摩四关穴对肝阳上亢证高血压患者的效果观察[J].中华护理杂志,2015,50(11):1322-1326.
[18] 李聪,李鹏,李志浩,等.马尾松松针的研究概况[J].国际中医中药杂志,2013,35(8):748-750.
[19] 程博琳,苗明三.葛根现代研究及应用特点分析[J].中医学报,2014,29(7):1014-1016.
[20] 韩珮,张春椿,熊耀康.珍珠粉临床应用的最新研究进展[J].中医学报,2011,26(7):835-837.